Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney–liver transplantation

摘要: Summary Fibrosing cholestatic hepatitis (FCH) is a classical but rare and severe form of recurrent C virus (HCV) after liver transplantation. Classical anti-HCV therapy, that pegylated-interferon (peg-interferon) ribavirin, has been shown to have limited efficacy in treating FCH. Herein, we report on the first case successful use peg-interferon, plus sofosbuvir treat HCV-induced FCH combined liver–kidney transplant patient. Antiviral therapy was given for 24 weeks. HCV clearance occurred within 4 weeks starting maintained until end therapy. tolerance good. We conclude sofosbuvir-based can be successfully used or kidney–liver